@hoperugo@OncoAlert@Ealvarezp2@PTarantinoMD Absolutely agree Hope. Crossover design should be encouraged here, The differentiators then we are left with inclusion/exclusion criteria and side effects
Huge congratulations to our incredible mentor, Dr. Mariana Chavez MacGregor, on being named @MDAndersonNews Mentor of the Year! I’m greatly appreciative of your guidance, unwavering support and sponsorship. So well deserved! ✨
Thanks to a generous $150 million gift from Kinder Foundation, we announce the launch of Kinder Children’s Cancer Center. This joint venture of UT MD Anderson and @TexasChildrens has a single mission: to #EndChildhoodCancer. https://t.co/QFBRpX3KKp #UTMDAnderson_TexasChildrens
To all SITC members - election starts May 2 and I would strongly encourage consideration of Dr. Tina Cascone as a dynamic and visionary physician scientist and translational researcher. A true pioneer and leader in the lung cancer space. @sitcancer
https://t.co/6Rykqz1mUR
We are pleased to announce that Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, has been appointed Editor-in-Chief of Clinical Cancer Research. Learn More: https://t.co/skkJsmsDvS
We’re days out from the ice storm that will impact blood supply @MDAndersonNews. Take 30 minutes this weekend (or during a half day on Monday) to make a difference by donating blood for our cancer patients. Make an appointment at https://t.co/PpAXi1mGjf. #EndCancer
Looking forward to this ALL STAR Jim Allison Institute symposium on #Immunotherapy in Space and Time at @MDAndersonNews tomorrow.
https://t.co/fOwNoniz3j
Starting tomorrow, MD Anderson experts will present the latest advances in cancer care at the European Society for Medical Oncology Congress.
Read highlights from presentations and details about onsite opportunities: https://t.co/VGqRJwvYkz @myESMO#ESMO24#EndCancer
Our Dr. Jason Westin shares insights on how CAR-T therapy could improve first-line therapy in some lymphoma patients: https://t.co/hOT6BbOs3I @Lymphoma_Doc#EndCancer
It was an honor to be part of the plenary session — especially to celebrate progress for patients with lung cancer and be with wonder colleagues. #LCSM
At #ASCO24? Be sure to stop by the @MDAndersonNews booth (#13069) for our Meet the Experts sessions and to grab a coffee. Find out more info at https://t.co/MyjGySeOfm. #EndCancer
The antibody drug conjugate M9140 demonstrates promising activity in heavily pretreated patients with advanced #ColorectalCancer.
Read about the findings presented by our Dr. Scott Kopetz (Abstract 3000) at #ASCO24: https://t.co/zsGxMQnSuL @skopetz@ASCO#EndCancer